Filtered By:
Source: Cancer Control
Drug: Fortamet
This page shows you your search results in order of date.
Order by Relevance | Date
Total 70 results found since Jan 2013.
Ultra-efficient radio-immunotherapy for reprogramming the hypoxic and immunosuppressive tumor microenvironment with durable innate immune memory
Biomaterials. 2023 Sep 5;302:122303. doi: 10.1016/j.biomaterials.2023.122303. Online ahead of print.ABSTRACTRadiosensitization efficacy of conventional tumor radiosensitizers has been frequently limited by insufficient competence for tumor microenvironment (TME) regulation and unfavorable cellular uptake at biological barriers. Here, we reported an ultra-efficient radiotherapy (RT) strategy by synthesizing an extracellular vesicles (EVs)-encapsulated hollow MnO2 to load metformin (Met@HMnER). It demonstrated significant RT enhancement by morphological control of catalyst and cellular respiratory depression against conventi...
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Jichun Yang Chong Zhang Xiaohui Chen Daijun Zhou Zixin Sun Ruyan Niu Ying Zhu Hengyi Chen Liu Wang Yi Chen Yuhan Wang Yunqian Fu Ningyu Ma Jianjun Li Yang Luo Source Type: research
Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action
This study aims to investigate the effect of metformin and aspirin and their combination of them on A549 and PC3 cell lines. Metformin and aspirin were investigated separately and in combination on two cancer cell lines, A549 and PC3. The examined groups include the negative control of untreated cells and the positive control of cisplatin and drugs at concentrations of 15, 10, and 20 μg/ mL to investigate the mechanism of oxidative stress factors (reactive oxygen species, lipid peroxidation, Glutathione (GSH)) and apoptosis (lactate dehydrogenase). The results showed that aspirin, metformin, and their combination could af...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Farzaneh Motafeghi Romina Shahsavari Parham Mortazavi Aysan Babaei Pouria SamadiMojaveri Omid Abed Khojasteh Mohammad Shokrzadeh Source Type: research
Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial
Conclusion: The use of metformin in breast cancer patients offered a marked protection against paclitaxel-induced PN, which translated to better patient QoL. Clinical Trial Registration: https://classic.clinicaltrials.gov/ct2/show/NCT05351021, identifier NCT05351021.PMID:37583905 | PMC:PMC10424931 | DOI:10.3389/fphar.2023.1181312
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Hala M Bakry Noha O Mansour Tawfik R ElKhodary Moetaza M Soliman Source Type: research
Injectable periodontal ligament stem cell-metformin-calcium phosphate scaffold for bone regeneration and vascularization in rats
CONCLUSIONS: The novel injectable construct with hPDLSC and Met encapsulation demonstrated excellent efficacy for bone regeneration and vascularization in vivo in an animal model. CPC+hPDLSCs+ 0.1%Met is highly promising for dental and craniofacial applications.PMID:37574338 | DOI:10.1016/j.dental.2023.07.008
Source: Cancer Control - August 13, 2023 Category: Cancer & Oncology Authors: Yaxi Sun Zeqing Zhao Qingchen Qiao Shengnan Li Wenting Yu Xiuchen Guan Abraham Schneider Michael D Weir Hockin H K Xu Ke Zhang Yuxing Bai Source Type: research
Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis
Conclusion: Sulfonylureas and insulin may increase the incidence of pancreatic cancer in diabetic patients, with varying effects observed among different ethnicities (Asian and Western). Due to significant heterogeneity across studies, further interpretation of the relationship between hypoglycemic agents and pancreatic cancer incidence in diabetic patients requires well-adjusted data and better-organized clinical trials.PMID:37497113 | PMC:PMC10366383 | DOI:10.3389/fphar.2023.1193610
Source: Cancer Control - July 27, 2023 Category: Cancer & Oncology Authors: Zimo Zhao Xinyi He Yan Sun Source Type: research
Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma
CONCLUSION: Reducing insulin feedback improves the efficacy of PI3K inhibition in glioblastoma in mice, and hyperglycemia worsens progression-free survival in patients with glioblastoma treated with PI3K inhibition. These findings indicate that hyperglycemia is a critical resistance mechanism associated with PI3K inhibition in glioblastoma and that anti-hyperglycemic therapy may enhance PI3K inhibitor efficacy in glioblastoma patients.PMID:37399061 | DOI:10.1093/neuonc/noad117
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Evan K Noch Laura N Palma Isaiah Yim Nayah Bullen Yuqing Qiu Hiranmayi Ravichandran Junbum Kim Andre Rendeiro Melissa B Davis Olivier Elemento David J Pisapia Kevin Zhai H Carl LeKaye Jason A Koutcher Patrick Y Wen Keith L Ligon Lewis C Cantley Source Type: research
Oxidative brain and cerebellum injury in diabetes and prostate cancer model: Protective effect of metformin
J Biochem Mol Toxicol. 2023 Jun 24:e23440. doi: 10.1002/jbt.23440. Online ahead of print.ABSTRACTThe body can host the spread of prostate cancer cells. Metastases from prostate cancer are more frequently seen in the brain, liver, lungs, and lymph nodes. A well-known antidiabetic drug, metformin, is also known to have antitumor effects. Our study focuses on the evaluation of potential metformin protective effects on brain and cerebellum damage in streptozotocin (STZ)-induced diabetic and Dunning prostate cancer models. In this investigation, six groups of male Copenhagen rats were created: control, diabetic (D), cancer (C),...
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Eda Dagsuyu P ınar Koroglu Ilknur B Gul Omur K Bulan Refiye Yanardag Source Type: research
Kr üppel-like factor 10 modulates stem cell phenotypes of pancreatic adenocarcinoma by transcriptionally regulating notch receptors
CONCLUSIONS: These results demonstrated a novel signaling pathway by which KLF10 modulates stem cell phenotypes in PDAC through transcriptionally regulating Notch signaling pathway. The elevation of KLF10 and suppression of Notch signaling may jointly reduce PDAC tumorigenesis and malignant progression.PMID:37308977 | DOI:10.1186/s12929-023-00937-z
Source: Cancer Control - June 12, 2023 Category: Cancer & Oncology Authors: Yi-Chih Tsai Kung Hung Cheng Shih Sheng Jiang John R Hawse Shun En Chuang Su Liang Chen Tze-Sing Huang Hui-Ju Ch'ang Source Type: research
Investigation of glycaemic and nutritional status of patients suffering from cancer.
CONCLUSION: Based on our results, targeted screening for cancer among diabetic patients, and seeking and adequately treating glycometabolic disorders with concomitant malignant conditions, respectively , are suggested, mainly using metformin and new non-insulin antidiabetic medicines. Through these efforts, the fight against cancer can be more effective. Orv Hetil. 2023; 164(23) 900-910.PMID:37302126 | DOI:10.1556/650.2023.32796
Source: Cancer Control - June 11, 2023 Category: Cancer & Oncology Authors: R óbert János Bánhegyi Blanka Ver éb Ádám Attila Mátrai Beatrix R ácz Szilvia Beke Source Type: research
Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
CONCLUSIONS: Although the metformin plus temozolomide regimen was well tolerated, it did not confer a clinical benefit in patients with recurrent or refractory GBM. Trial registration NCT03243851, registered August 4, 2017.PMID:37278858 | DOI:10.1007/s12672-023-00678-3
Source: Cancer Control - June 6, 2023 Category: Cancer & Oncology Authors: Wan-Soo Yoon Jong Hee Chang Jeong Hoon Kim Yu Jung Kim Tae-Young Jung Heon Yoo Se-Hyuk Kim Young-Cho Ko Do-Hyun Nam Tae Min Kim Se Hoon Kim Sung-Hae Park Youn Soo Lee Hyeon Woo Yim Yong-Kil Hong Seung Ho Yang Source Type: research
Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors
Conclusion: The findings that metformin decreases cell-surface HER receptors and reduces antibody-tumor binding may have significant implications for the use of antibodies targeting these receptors in cancer treatment and molecular imaging.PMID:37268425 | DOI:10.2967/jnumed.122.265248
Source: Cancer Control - June 2, 2023 Category: Cancer & Oncology Authors: Sandeep Surendra Panikar Nai Keltee Na-Keysha Berry Shayla Shmuel Zachary T Fisher Emma Brown Abbey Zidel Alex Mabry Patr ícia M R Pereira Source Type: research
Drug repurposing: Metformin's effect against liver tissue damage in diabetes and prostate cancer model
CONCLUSION: These highlights that the antidiabetic drug metformin can be repositioned for attenuating liver tissue damage associated with prostate cancer and diabetes.PMID:37255805 | PMC:PMC10225428 | DOI:10.1007/s40200-022-01109-w
Source: Cancer Control - May 31, 2023 Category: Cancer & Oncology Authors: P ınar Koroglu Aydın Ismet Burcu Turky ılmaz Ilknur Bugan Gul Omur Karabulut Bulan Refiye Yanardag Source Type: research
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
Biomedicines. 2023 Apr 6;11(4):1105. doi: 10.3390/biomedicines11041105.ABSTRACTSince prostate cancer (PCa) was described as androgen-dependent, the androgen receptor (AR) has become the mainstay of its systemic treatment: androgen deprivation therapy (ADT). Although, through recent years, more potent drugs have been incorporated, this chronic AR signaling inhibition inevitably led the tumor to an incurable phase of castration resistance. However, in the castration-resistant status, PCa cells remain highly dependent on the AR signaling axis, and proof of it is that many men with castration-resistant prostate cancer (CRPC) s...
Source: Cancer Control - May 16, 2023 Category: Cancer & Oncology Authors: Bel én Congregado Ruiz In és Rivero Belenchón Guillermo Lend ínez Cano Rafael Antonio Medina L ópez Source Type: research
MET Inhibits the Proliferation of EC Cells by Increasing MPA Sensitivity
CONCLUSIONS: MET inhibited the proliferation of EC cells by increasing MPA-sensitivity, which was dependent on the inhibition of the CD133 expression and the Akt/mTOR pathway. In addition, if MET acts as an effective progestin sensitizer, it certainly offers promising therapeutic prospects for patients with early-stage EC or overgrown endometrium who have fertility requirements.PMID:37171945
Source: Cancer Control - May 12, 2023 Category: Cancer & Oncology Authors: Fang Sun Jiayun Zhou Yongxin Hao Lei Kuang Bei Zhang Source Type: research
Clinical and metabolic characteristics of endometrial lesions in polycystic ovary syndrome at reproductive age
CONCLUSION: Obesity, prolonged menstrual cycle, decreased SHBG, and dyslipidemia are risk factors for EH in patients with PCOS. Oral contraceptives, progestogen and metformin are recommended for prevention and treatment of endometrial lesions in PCOS patients.PMID:37149578 | DOI:10.1186/s12905-023-02339-7
Source: Cancer Control - May 6, 2023 Category: Cancer & Oncology Authors: Xiaozhu Zhong Yang Li Weiying Liang Qiyue Hu Anqi Zeng Miao Ding Dongmei Chen Meiqing Xie Source Type: research
